Blinatumomab functions as a bispecific T-cell engager (BiTE), targeting tumor cells for destruction by simultaneously blinding to tumor-specific antigens (CD19 antigen on malignant B cells) and patients’ own T-cell receptors (typically CD3ε) (8). Here, CD19 is linked to neoplasm.